Kazia Therapeutics CEO Dr James Garner was interviewed recently by Morgans Senior Analyst Scott Power about Kazia’s upcoming milestones and clinical trials.
Dr Garner discusses:
- The timeline for the next milestones for the trial of Cantrixil, a potential drug for recurrent ovarian cancer
- Why there’s a need for treatments for the brain cancer glioblastoma multiforme, for which Kazia is developing GDC-0084
- The company’s current cash position and burn rate
